Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 63 Neoplasms 7 Neoplasms, Plasma Cell 6 Recurrence 5 Hematologic Neoplasms 4 Renal Insufficiency 3 Paraproteinemias 3 Lymphoma 3 Immunoglobulin Light-chain Amyloidosis 3 Hematologic Diseases 3 Smoldering Multiple Myeloma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms by Histologic Type 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Blood Protein Disorders 2 Purpura 1 Prostatic Neoplasms 1 Neoplasm, Residual 1 Nausea 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoproliferative Disorders 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Immunoproliferative Disorders 1

Interventions

Dexamethasone 21 Calcium Dobesilate 10 Melphalan 9 Bortezomib 8 Cyclophosphamide 7 Lenalidomide 6 pomalidomide 4 miridesap 3 daratumumab 3 venetoclax 2 ixazomib 2 belantamab mafodotin 2 Thalidomide 2 Doxycycline 2 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2 selinexor 1 pegfilgrastim 1 isatuximab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carfilzomib 1 birtamimab 1 auricularum 1 Vinorelbine 1 Technetium Tc 99m Pyrophosphate 1 Technetium 1 Tacrolimus 1 Surveys and Questionnaires 1 Pharmaceutical Preparations 1 Lisaftoclax 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Amyloidosis × isatuximab × Clear all

NCT05066607 2024-03-06

IsAMYP

Intergroupe Francophone du Myelome

Phase 2 Unknown

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡